Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

Introduction: Trastuzumab emtansine (T-DM1) significantly improves invasive disease-free survival and reduces the risk of recurrence in patients with HER2-positive early breast cancer (EBC) with residual disease (RD). The KARMA study aimed to describe the characteristics and management of these pati...

Full description

Bibliographic Details
Main Authors: Silvia Antolín Novoa, Santiago Escrivá-de-Romaní, Pablo Tolosa Ortega, Lucía Oliva Fernández, Rafael López López, Ana López González, Pilar de la Morena Barrio, Isabel Echavarria Díaz-Guardamino, José Enrique Alés Martinez, Zita Garate, Lucia González-Cortijo
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Early breast cancer
Human epidermal growth factor receptor-2 (HER2)
Adjuvant treatment
Trastuzumab emtansine (T-DM1)
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294223000941

Internet

http://www.sciencedirect.com/science/article/pii/S2468294223000941

Similar Items